Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after one systemic therapy

Dwayne Boyers, Moira Cruickshank, Neil Scott, Elisabet Jacobsen, Sachin Kumar, Mari Imamura, Paul Manson, Gavin Preston, Miriam Brazzelli* (Corresponding Author)

*Corresponding author for this work

Research output: Book/ReportCommissioned Report

Abstract

Evidence Review Group report in support of NICE STA Programme.
Original languageEnglish
Place of PublicationLondon
PublisherEvidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence
Number of pages128
Publication statusPublished - 20 Jun 2022

Bibliographical note

Source of funding: This report was commissioned by the NIHR Systematic Reviews Programme as project number 135560.

Fingerprint

Dive into the research topics of 'Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after one systemic therapy'. Together they form a unique fingerprint.

Cite this